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Hypercoagulability has been implicated as a
cause of deep vein thrombosis (DVT) in 5% to 10%
of patients.1,2 This finding is of particular impor-
tance because these patients tend to experience
recurrent DVT with the potential for pulmonary
embolism and are often subjected to life-long anti-
coagulation with coumadin. Conversely, little atten-
tion has been given to superficial thrombophlebitis
because of the perceived notion that it is a self-lim-
iting condition. Although this is generally true for
acute thrombosis of the branches of the saphenous
vein, the natural history of superficial throm-
bophlebitis of the main trunk may not be as benign.
In fact, we and others have reported an association
of saphenous vein thrombophlebitis (SVT) with
DVT ranging from 17% to 40%.3,4 In addition, the
progression of the thrombotic process from the
greater or lesser saphenous veins into the deep
venous system has previously been documented.5,6
Moreover, a recurrence rate for SVT of 5% to 49%7,8
may be explained by systemic rather than local fac-
tors. Thus, it is conceivable that a hypercoagulable
state may also be related to SVT. Accordingly, we
have attempted to elucidate the cause of isolated
greater or lesser SVT in 17 consecutive patients
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Purpose: The association between deep vein thrombosis (DVT) and the hypercoagulable
state is a well-established entity. However, the association between saphenous vein
thrombophlebitis and coagulation abnormalities has not been investigated. Although
thrombosis of varicose veins typically runs a benign course, phlebitis of the saphenous
system may propagate to the deep system or saphenofemoral junction that requires more
aggressive therapy. Given the potential similarity in clinical outcome between saphenous
vein thrombophlebitis (SVT) and DVT, we have investigated the coagulation profile of
patients presenting with isolated SVT.
Methods: Seventeen consecutive patients who presented to our vascular laboratory with
isolated SVT had a coagulation profile performed that included antithrombin III (AT
III), protein C (PC), protein S (PS) antigen and activity levels, activated protein C (APC)
resistance, factor V DNA mutation, and coagulation factors II and X. All patients had
duplex scans performed on both the superficial and deep venous systems. Patients with
SVT only were treated with nonsteroidal antiinflammatory drugs (NSAIDs) and warm
soaks as outpatients, whereas those patients found to have DVT or a clot at the saphe-
nofemoral junction were fully anticoagulated with heparin and coumadin therapy. All 17
patients had at least one repeat coagulation profile performed up to 5 months after their
SVT occurrence to ensure that the results of hypercoagulability were not transient.
Results: Ten (59%) of the 17 patients with SVT had abnormal coagulation profiles on
initial presentation. All 10 patients who were hypercoagulable had repeat tests and 6
(35%) remained abnormal. Four patients who had abnormal results converted to normal
values. Seven patients with normal coagulation profiles on initial presentation had repeat
tests and all remained normal.
Conclusion: The incidence of the hypercoagulable state in patients with SVT is high.
Thirty-five percent of patients with isolated SVT had consistently abnormal coagulation
profiles. Patients with SVT may be prone to the development of DVT or saphenofemoral
junction thrombophlebitis and should be closely followed after the initial diagnosis of
hypercoagulability. (J Vasc Surg 1998;27:677-80.)
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referred to our institution over the last 21 months
by performing extensive coagulation studies.
PATIENTS AND METHODS
Examination of 3714 lower extremity venous
duplex scans performed from August 1995 to April
1997 at Maimonides Medical Center identified 32
patients with SVT. Patients identified as having
simultaneous DVT and SVT were not entered into
the study. Patients with underlying malignancies
were also not entered into the study. The study
group consisted of patients with isolated SVT: 6
men and 11 women, with ages ranging from 36 to
77 years (mean = 60.8 years). 
Both the superficial and deep venous systems
were examined bilaterally with a standard method of
examination. Starting at the saphenofemoral junc-
tion and continuing distally to the tibial and per-
oneal veins, transverse and longitudinal views were
obtained. The diagnosis of venous thrombosis was
made if there was no spontaneous flow in the veins
with respiration and augmentation maneuvers,
echogenic signals were found within the vein lumen,
and the vein was unable to be compressed with the
transducer.
Patients with saphenofemoral junction throm-
bophlebitis (SFJT) were hospitalized, placed on strict
bed rest with leg elevation, and anticoagulated.
Intravenous heparin was administered to obtain a
partial thromboplastin time 1.5 to 2.0 times greater
than control levels. Twenty-four hours later,
coumadin was started and the patient was maintained
on a dosage sufficient to attain an international nor-
malized ratio (INR) in the recommended range of
2.0 to 3.09 and the heparin was subsequently discon-
tinued. Two to four days after hospital admission, a
follow-up bilateral duplex scan was performed, reex-
amining both the superficial and deep venous sys-
tems. Patients with DVT were kept on coumadin for
6 months, whereas patients with SFJT alone were
maintained on coumadin for 6 weeks.1,3 Those
patients with thrombophlebitis isolated to the greater
saphenous vein or lesser saphenous vein were treated
with warm compresses, nonsteroidal antiinflammato-
ry drugs, compression stockings, and ambulation. 
A coagulation profile was taken at the time of the
initial diagnosis of SVT. The coagulation profile
included: (1) protein C antigen and activity level, (2)
activated protein C (APC) resistance, (3) protein S
antigen and activity level, (4) antithrombin III (AT
III) antigen and activity level, and (5) factor V DNA
mutation. Factor II and factor X levels were also
determined to verify the absence of acquired protein
deficiencies and to be used to determine the presence
of hypercoagulability in patients with deficiencies of
protein C and protein S who were also on coumadin.
To determine whether the protein C and protein S
values were valid, the protein C and protein S to fac-
tor X ratios were calculated. The protein S to factor
X ratio must be less than 0.9 while on coumadin for
true protein S deficiency; whereas the protein C to
factor X ratio must be less than 0.5 while on
coumadin for true protein C deficiency.10,11
No patient was on heparin and one was taking
coumadin (for a history of DVT 4.5 months prior)
at the time of the initial blood tests. No patient had
liver disease or DIC and there was no known family
history of DVT. All patients denied any history of
lower extremity trauma.
Repeat blood tests were obtained when available
to ensure that any deficient proteins were not due to
consumption of regulatory proteins of the coagula-
tion system.
All assays were performed at SmithKline
Beecham Clinical Laboratories (Syosset, N.Y.), with
standard techniques by technicians unaware of the
patients clinical diagnosis. Assays used included the
Staclot protein C clotting assay, Asserachrom pro-
tein C enzyme immunoassay, the Staclot protein S
clotting assay, Asserachrom protein S enzyme
immunoassay, Scripps APC resistance coagulation
assay for abnormal factor V, Beckman antithrombin
III antigen assay, and Baxter Diagnostics antithrom-
bin III chromogenic assay.
RESULTS
All 17 patients entered into the study had at least
two coagulation profiles performed. Ten (59%) of
the 17 patients with SVT had an abnormal coagula-
tion profile on initial presentation. All patients who
were hypercoagulable had repeat tests and 6 (35%)
of the 17 remained abnormal. Seven patients with
normal coagulation profiles on the initial presenta-
tion had repeat tests and all 7 remained normal.
Coagulation profiles were then compared with
location of thrombus. Five (36%) of 14 patients with
great saphenous vein thrombophlebitis (GSVT) were
consistently hypercoagulable. Two patients had AT
III deficiency only, 1 patient had AT III and protein
S deficiencies, 1 patient had protein S deficiency only,
and 1 patient had protein S deficiency and APC resis-
tance. Three patients had SFJT. One of these patients
(33%) had AT III, protein S, and protein C deficien-
cies. These results were unchanged on repeat exami-
nation. All patients who had normal coagulation pro-
files initially remained normal on repeat examination.
JOURNAL OF VASCULAR SURGERY
678 Hanson et al. April 1998
The 1 patient who was on coumadin at the time
of the coagulation profile testing had abnormal find-
ings. This patient had AT III, protein C and protein
S deficiencies and was considered truly hypercoagu-
lable because coumadin does not affect AT III levels.
Follow-up duplex examinations were obtained in
13 (76%) of 17 patients. Six examinations remained
unchanged, 1 improved, and 6 worsened. Three of
the 6 patients with unchanged examinations were
hypercoagulable and 3 of the 6 patients with wors-
ened duplex examinations were hypercoagulable (1
patient had SFJT affected initially, which progressed
down to the lower calf, 1 patient had extension of
GSVT proximally but did not involve the SFJ, and 1
patient had extension of clot within the main trunk
of the greater saphenous vein).
DISCUSSION
Deficiencies of proteins involved in the coagula-
tion system are associated with an enhanced risk of
venous thromboembolism.1 Three major naturally
occurring anticoagulants that contribute to the
thrombotic state when deficient are AT III (the
major plasma inhibitor of the coagulation enzymes
thrombin and factor Xa), protein C (a vitamin K
dependent protein that inactivates coagulation fac-
tors Va and VIIIa), and protein S (also a vitamin K
dependent protein that serves as cofactor to protein
C). Activated protein C resistance, which can be
attributed to factor V DNA mutation, has also been
cited as contributing to hypercoagulability.12-14
Although coagulation protein abnormalities have
been associated with DVT,15-17 no such relationship
has been established with SVT.
We have investigated the incidence of hyperco-
agulability in patients presenting with isolated SVT
and found an incidence of 35%. Ten of the 17
patients with abnormal coagulation profiles under-
went repeat testing and 6 patients (35%) remained
hypercoagulable. The active process of thrombosis
sometimes consumes coagulation protein such that
the patients appear deficient when tested during
acute thrombosis. Thus, it may be necessary to
repeat abnormal tests at a time remote from the ini-
tial diagnosis test to demonstrate “true” hypercoag-
ulability. Repeat coagulation profiles were per-
formed no earlier than 1 week after diagnosis of SVT
and up to 5 months after diagnosis and these were
correlated with follow-up duplex scans. The patients
in this series all had weekly duplex scans to docu-
ment the status of the thrombophlebitis (to ensure
that the clot was considered stable, by evidence of
clot adherence to the vessel wall and the presence of
a hyperechoic signal). The 4 patients whose coagu-
lation profile became normal on repeat testing were
not considered hypercoagulable. In addition, 7
patients with normal studies had repeat examina-
tions and all 7 remained unchanged. Thus, our data
suggest that once a patient is found to have a normal
coagulation profile deficiency in the presence of
acute SVT, it is not necessary to repeat the test.
Four of the 6 patients found to be hypercoagula-
ble had AT III deficiency, either alone or in combi-
nation with some other abnormality, making it the
most common finding that concurs with the findings
of others.18 There was one case of isolated PS defi-
ciency and one case of APC resistance with PS defi-
ciency. 
Thus, the incidence of the hypercoagulable state
in patients with the GSVT (35%) underscores the
necessity for repeat testing when abnormal values are
found.
It is generally accepted that persons younger
than 40 years of age, or patients with unexplained
recurrent venous thrombotic episodes are very like-
ly to have a hypercoagulable disorder. In this study,
1 (17%) of 6 patients who was found to have coag-
ulation protein abnormalities was younger than age
40; whereas 5 patients (83%) were older than age
40. This rebukes the trend that hypercoagulability
tends to be a disease most commonly found in
young people and indicates that older patients
should be worked up for hypercoagulability as well.
In addition, gender was not associated with an
increased likelihood of coagulation abnormalities in
our series. One of the 6 men was hypercoagulable;
while 5 of the 11 women had similar findings (p >
0.05).
Although DVT is the more common manifesta-
tion of a congenital deficiency of AT III, protein C or
protein S, or APC resistance, the development of an
isolated SVT is reported to be the initial presentation
in 11% of symptomatic protein C deficient cases 19
and 15% of protein S cases. 20 In addition, 50% of
recurrent thrombotic episodes due to congenital
thrombophilia occur in the superficial venous sys-
tem.11 As these findings have been based solely on a
clinical diagnosis of SVT, the occurrence of SVT is
probably underestimated. The use of the duplex scan
as a screening tool is to identify patients who may
have subclinical superficial thrombophlebitis. This
group of patients may have subclinical SVT as the
only indication of a hypercoagulable state (in a non-
high risk situation). Identification of these people
may have an impact on decreasing the formation of
outright venous thromboses and their complications.
JOURNAL OF VASCULAR SURGERY
Volume 27, Number 4 Hanson et al. 679
It is true that patients presenting to a vascular
laboratory may have a more virulent form of throm-
bophlebitis, however, the data from this series sug-
gest that patients with anticoagulant deficiencies and
SVT may actually be a more common manifestation
of the hypercoagulable state than previously docu-
mented.
CONCLUSION
In this series of 17 patients with superficial
thrombophlebitis, those with GVST were found to
have a higher incidence of coagulation protein
abnormalities than expected. The clinical impact of
this finding will require a much longer follow-up in
a substantially larger group of patients. Because a
hypercoagulable state is not generally considered a
benign condition, one can assume that GSVT may
be a deceptively benign disease.
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